Evommune, Inc. 8-K

What Happened

• Evommune, Inc. filed an 8-K disclosing the results of its 2026 Annual Meeting of Stockholders held June 2, 2026 (a quorum was present). Stockholders elected Luis Peña and Eugene Bauer, M.D. to the Board of Directors to serve until the 2029 Annual Meeting or until their successors are elected. The meeting also ratified BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The Company’s definitive proxy statement was filed April 21, 2026. The filing was signed by Luis Peña, President and CEO.

Key Details

• Luis Peña: 21,859,596 votes For, 1,949,148 Withheld, 885,750 Broker Non-Votes.
• Eugene Bauer, M.D.: 23,637,920 votes For, 170,824 Withheld, 885,750 Broker Non-Votes.
• Ratification of auditor (BDO USA, P.C.): 24,664,299 For, 430 Against, 29,765 Abstain, 0 Broker Non-Votes.
• Meeting date: June 2, 2026; elected directors’ terms run through the 2029 Annual Meeting (or until successors are qualified).

Why It Matters

• Board composition and continuity: Election results confirm the incumbency/appointment of two directors, which affects corporate governance and oversight through at least 2029.
• Auditor ratification: Stockholder approval of BDO USA, P.C. confirms the firm that will audit Evommune’s financial statements for 2026, an item relevant to financial reporting and investor confidence.
• Practical impact: These are governance routine actions disclosed for transparency; there were no other material operational or financial announcements in this filing.